Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

CAPR Capricor Therapeutics

Watchlist
6.240
+0.140+2.30%
Close 10/04 16:00 ET
6.190
-0.05-0.80%
Post Mkt Price 10/04 17:07 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
6.325
Open
6.160
Turnover
1.66M
Low
6.160
Pre Close
6.100
Volume
264.42K
Market Cap
151.92M
P/E(TTM)
Loss
52wk High
6.325
Shares
24.35M
P/E(Static)
Loss
52wk Low
2.560
Float Cap
147.53M
Bid/Ask %
-60.00%
Historical High
7999.998
Shs Float
23.64M
Volume Ratio
1.52
Historical Low
0.880
Dividend TTM
--
Div Yield TTM
--
P/B
8.11
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.12%
Amplitude
2.71%
Avg Price
6.262
Lot Size
1
Float Cap
147.53M
Bid/Ask %
-60.00%
Historical High
7999.998
Shs Float
23.64M
Volume Ratio
1.52
Historical Low
0.880
Dividend TTM
--
P/B
8.11
Dividend LFY
--
Turnover Ratio
1.12%
Amplitude
2.71%
Avg Price
6.262
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
CEO: --
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top